Citius Pharmaceuticals, Inc. (CTXR)
0.5316
-0.01
(-1.59%)
USD |
NASDAQ |
Oct 02, 16:00
0.5315
0.00 (0.00%)
After-Hours: 20:00
Citius Pharmaceuticals Gross Profit Margin (Quarterly) : -48.09% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -48.09% |
| March 31, 2026 | -22.91% |
| Date | Value |
|---|---|
| December 31, 2025 | 65.45% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
| Johnson & Johnson | 68.73% |
| Eli Lilly & Co. | 85.78% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -75.83% |
| Return on Assets | -43.15% |
| Return on Invested Capital | -73.25% |
| Profit Margin (Quarterly) | -797.9% |
| Operating Margin (Quarterly) | -785.4% |
| Return on Net Operating Assets | -45.89% |